Recent progress in protein farnesyltransferase inhibition

IDrugs

Volumn 3, Issue 11, 2000, Pages 1336-1345

  Lamothe, Marie ^a   Perez, Michel ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001659853     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. Silvius JR: Lipid modifications of intracellular signal-transducing proteins. J Liposome Res (1999) 9(1):1-19.
2. Zhang H, Seabra MC, Deisenhofer J: Crystal structure of Rab geranylgeranyltransferase at 2.0 Å resolution. Structure (2000) 8:241-251.
3. ras protein farnesytransferase. Proc Natl Acad Sci USA (1991) 88:732-736.
4. Moores SL, Schaber MD, Mosser SD, Rands E, O'Hara MB, Garsky VM, Marshall MS, Pompliano DL, Gibbs JB: Sequence dependence of protein isoprenylation. J Biol Chem (1991) 266:14603-14610.
5. Clarke S: Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem (1992) 61:355-386.
6. ras farnesyl: protein transferase by Cys-AAX tetrapeptides. Cell (1990) 62:81-88.
7. Halazy S, Gotteland J-P, Lamothe M, Perrin D, Hill BT: Rationally designed FPTase inhibitors. Drugs Future (1997) 22:1133-1146.
8. Barbacid M: ras Genes. Annu Rev Biochem (1987) 56:779-827.
9. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ: Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA (1992) 89:6403-6407.
10. Garcia AM, Rowell C, Ackermann K, Kowalczyk JJ, Lewis MD: Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J Biol Chem (1993) 268:18415-18418.
11. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC: Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (1993) 260:1937-1942.
12. Kohl NE, Mosser SD, deSolms J, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (1993) 260:1934-1937.
13. Gibbs JB, Graham SL, Hartman GD, Koblan KS, Kohl NE, Omer CA, Oliff A: Farnesyltransferase inhibitors versus Ras inhibitors. Curr Opin Chem Biol (1997) 7:197-203.
14. Cox AD, Der CJ: Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochimi Biophys Acta (1997) 1333:F51-F71.
15. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N: A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and - independent growth of human tumor cell lines. Cancer Res (1995) 55:5302-5309.
16. Nagasu T, Yoshimatsu K, Rowel C, Lewis MD, Garcia AM: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res (1995) 55:5310-5314.
17. Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L, Patton R, Windsor WT, Syto R, Zhang R, Bishop WR: Characterization of Ha-Ras, N-Ras, Ki-RasA4, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgenaryl protein transferase type I. J Biol Chem (1997) 272:10232-10239.
18. James GL, Goldstein JL, Brown MS: Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem (1995) 270:6221-6226.
19. Sun J, Qian Y, Hamilton AD, Sebti SM: Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene (1998) 16(11):1467-1473.
20. End D, Skrzat S, Devine A, Angibaud P, Venet M, Sanz G, Bowden C: R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): biochemical and cellular effects in H-ras and K-ras dominant systems. Proc Am Assoc Cancer Res (1998) 39:1847.
21. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin C-C, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, Kirschmeier P, Bishop WR: Antitumor activity of Sch-66336, an orally bioavailable tricyclic inhibitor of farnesyl transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res (1998) 58:4947-4956.
22. Prendergast GC, Davide JP, DeSolms SJ, Giuliani EA, Graham SL, Gibbs JB, Oliff A, Kohl NE: Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol (1994) 14:4193-4202.
23. Mackay DJG, Hall A: Rho GTPases. J Biol Chem (1998) 273:20685-20688.
24. Prendergast GC: Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol (2000) 12:166-173.
25. Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM: Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem (2000) 275:17974-17978.
26. Andres DA, Goldstein JL, Ho YK, Brown MS: Mutational analysis of α-subunit of protein farnesyltransferase. J Biol Chem (1993) 263:1383-1390.
27. Omer CA, Kral AM, Diehl RE, Prendergast GC, Powers S, Allen CM, Gibbs JB, Kohl NE: Charaterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl dophosphate binding, and functional homology with yeast prenyl-protein transferases. Biochemistry (1993) 32:5167-5176.
28. Park H-W, Boduluri SR, Moomaw JF, Casey PJ, Beese LS: Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science (1997) 275:1800-1804.
29. Long SB, Casey PJ, Beese LS: The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 Å resolution ternary complex structures. Structure (2000) 8:209-222.
30. Hightower KE, Huang C-C, Casey PJ, Fierke CA: H-Ras peptide and protein substrates bind protein farnesyltransferase as an ionized thiolate. Biochemistry (1998) 37:15555-15562.
31. Pompliano DL, Schaber MD, Mosser SD, Omer CA, Shafer JA, Gibbs JB: Isoprenoid diphosphate utilization by recombinant human farnezyl: protein transferase: interactive between substrates and a preferred kinetic pathway. Biochemistry (1993) 32:8341-8347.
32. Furfine ES, Leban JJ, Landavazo A, Moomaw JF, Casey PJ: Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. Biochemistry (1995) 34:6857-6862.
33. Tschantz WR, Furfine ES, Casey PJ: Substrate binding is required for release of product from mammalian protein farnesyltransferase. J Biol Chem (1997) 272:9989-9993.
34. Strickland CL, Windsor WT, Syto R, Wang L, Bond R, Wu Z, Schwartz J, Le HV, Beese LS, Weber PC: Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. Biochemistry (1998) 37:16601-16611.
35. Stradley SJ, Rizo J, Gierasch ML: Conformation of a heptapeptide substrate bound to protein farnesyltransferase. Biochemistry (1993) 32:12586-12590.
36. ras farnesyl-transferase. J Biol Chem (1994) 269:12410-12413.
37. Cassidy PB, Dale Poulter C: Transition state analogs for protein farnesyltransferase. J Am Chem Soc (1996) 118:8761-8762.
38. Wu Z, Demma M, Strickland CL, Radisky ES, Poulter CD, Le HV, Windsor WT: Farnesyl protein transferase: identification of K164α and Y300β as catalytic residues by mutagenesis and kinetic studies. Biochemistry (1999) 38:11239-11249.
39. Omer CA, Kral AM, Diehl RE, Prendergast GC, Powers S, Allen CM, Gibbs JB, Kohl NE: Characterization of recombinant human farnesyl-protein transferase: Cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases. Biochemistry (1993) 32:5167-5176.
40. Chen W-J, Moomaw JF, Overton L, Kost TA, Casey PJ: High level expression of mammalian protein farnesyltransferase in a baculovirus system. J Biol Chem (1993) 268:9675-9680.
41. Scholten JD, Zimmerman KK, Oxender MG, Leonard D, Sebolt-Leopold J, Gowan R Hupe DJ: Synergy between anions and farnesyldiphosphate competitive inhibitors of farnesyl: protein transferase. J Biol Chem (1997) 272:18077-18081.
42. Huber HE, Abrams M, Anthony N, Graham S, Hartman G, Lobell R, Lumma W, Nahas D, Robinson R, Sisko J, Heimbrook DC: Biochemical evaluation of specific geranyltransferase inhibitors. Proc Am Assoc Cancer Res (2000) 41:2838.
43. Hill BT, Perrin D, Kruczynski A: Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited. CRC Crit Rev Oncol Hematol (2000) 33:7-23.
44. Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Bux Singh S, Scolnick EM, Kohl NE, Oliff A: Selective inhibition of farnesyl-protein transferase blocks Ras processing in vivo. J Biol Chem (1993) 268:7617-7620.
45. Dinsmore CJ, Bergman JM, Wei DD, Blair Zartman C, Gibbs JB, Koblan KS, Kohl NE, Lobell RB, Oliff AI, Chen I-W, Olah TV, Graham SL, Hartman GD, Williams TM: Oxo-derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase. ACS (2000) (San Francisco): MEDI 52.
46. Manne V, Ricca C, Gullo-Brown J, Penhallow B, Carboni J, Lynch M: BMS-214662, a nonthiol small molecule farnesyltransferase inhibitor. Proc Am Assoc Cancer Res (2000) 41:2835.
47. Rose WC, Arico MA, Burke CL, Clark JL, Fager KL, Van Deren C, Kramer RA, Lee FYF: Preclinical antitumor activity of BMS-214662, a novel farnesyltransferase inhibitor. Proc Am Assoc Cancer Res (2000) 41:2836.
48. Manne V, Ricca C, Gullo-Brown J, Penhallow B, Roongta U, Menendez A, Lee F, Monticello T, Lynch M: BMS-214662, a highly potent apoptotic farnesyltransferase inhibitor. Proc Am Assoc Cancer Res (2000) 41:1399.
49. Bol DK, Dell J, Ho CP, Swerdel M, Ricca C, Manne V: A comparison of the therapeutic and preventive efficacy of a novel Ras farnesyltransferase inhibitor endogenous mouse carcinogenesis models. Proc Am Assoc Cancer Res (2000) 41:1400.
50. O'Connor SJ, Barr KJ, Le Wang, Sorensen BK, Tasker AS, Sham H, Ng S-C, Cohen J, Devine E, Cherian S, Saeed B, Zhang H, Yun Lee J, Warner R, Tahir S, Kovar P, Ewing P, Alder J, Mitten M, Leal J, Marsh K, Bauch J, Hoffman DJ, Sebti SM, Rosenberg SH: Second-generation peptidomimetric inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy. J Med Chem (1999) 42:3701-3710.
51. Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailez RD, Hamilton AD, Sebti SM: Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine. Cancer Res (1999) 59:4919-4926.
52. Njoroge FG, Taveras AG, Kelly J, Remiszewski S, Mallams AK, Wolin R, Afonso A, Cooper AB, Rane DF, Liu Y-T, Wong J, Vibulbhan B, Pinto P, Deskus J, Alvarez CS, Del Rosario J, Connolly M, Wang J, Desai J, Rossman RR, Bishop WR, Patton R, Wang L, Kirschmeier P, Bryant MS, Nomeir AA, Lin CC, Liu M, McPhail AT, Doll RJ, Girijavallabhan VM, Ganguly AK: (+)-4-[2-[4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cycloheptal-[1,2-b] -pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidine carboxamide (SCH-63336): A very potent farnesyl protein transferase inhibitor as a novel antitumor agent. J Med Chem (1998) 41:4890-4902.
53. Strickland CL, Weber PC, Windsor WT, Wu Z, Le HV, Albanese MM, Alvarez CS, Cesarz D, Del Rosario J, Deskus J, Mallams AK, Njoroge GF, Piwinski JJ, Remiszewski S, Rossman RR, Taveras AG, Vibulbhan B, Doll RJ, Girijavallabhan VM, Ganguly AK: Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure activity relationships. J Med Chem (1999) 42:2125-2135.
54. Petit T, Izbicka E, Lawrence RA, Bishop WR, Weitman S, Von Hoff DD: Activity of Sch-66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Ann Oncol (1999) 10:449-453.
55. Shi B, Gumani M, Yaremko B, Lee S, Chen J, Lipari P, Ferrari E, Malkowski M, Liu M, Hajian G, Nielsen LL: Enhanced efficacy of the farnesyl protein transferase inhibitor Sch-66336 in combination with paclitaxel. Proc Am Assoc Cancer Res (1999) 40:3457.
56. Nielsen LL, Shi B, Hajian G, Yaremko B, Lipari P, Ferrari E, Gurnani M, Malkowski M, Chen J, Bishop WR, Liu M: Combination therapy with the farnesyl protein transferase inhibitor Sch-66336 and Sch-58500 (p53 adenovirus) in preclinical cancer models. Cancer Res (1999) 59:5896-5901.
57. Venet M, Angibaud P, Sanz G, Poignet H, End D, Bowden C: Synthesis and in vitro structure-activity relationships of imidazolyl-2(1H) quinolinones as farnesyl transferase inhibitors (FTI). Proc Am Assoc Cancer Res (1998) 39:2171.
58. Skrzat S, Angibaud P; Venet M, Sanz G, Bowden C, End D: R115777, a novel imidazole farnesyl protein transferase inhibitor with potent oral antitumor activity. Proc Am Assoc Cancer Res (1998) 39:2169.
59. Heliez C, Delmas C, Bonnet J, Moyal E, End D, Daly-Schveitzer N, Favre G, Toulas C: Farnesyl transferase inhibitor R115777 radiosensitizes human glioma cell lines. Proc Am Assoc Cancer Res (1999) 40:4219.
60. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol (2000) 18:927-941.
61. Giraud E, Luttmann C, Lavelle F, Riou J-F, Mailliet P, Laoui A: Multivariate data analysis using D-optimal designs, partial least squares, and response surface modelings: a directional approach for the analysis of farnesyltransferase inhibitors. J Med Chem (2000) 43:1807-1816.
62. Vrignaud P, Bissery MC, Mailliet P, Lavelle F: RPR 130401, a nonpeptidomimetic farnesyltransferase inhibitor with in vivo activity. Ann NY Acad Sci (1999) 886:249-251.
63. McNamara DJ, Dobrusin E, Leonard DM, Shuler KR, Kaltenbronn JS, Quin III J, Bur S, Thomas CE, Doherty AM, Scholten JD, Zimmerman KK, Gibbs BS, Gowan RC, Latash MP, Leopold WR, Przybranowski SA, Sebolt-Leopold JS: C-terminal modifications of histidyl-N-benzyglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice. J Med Chem (1997) 40:3319-3322.
64. Leonard DM et al: Histidine-(N-benzylglycinamides): structure-activity studies optimizing potency against ras farnesyl transferase. Proc Am Assoc Cancer Res (1997) 38:2342.
65. Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KT, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey HH: Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res (2000) 6:390-396.
66. Gelb MH, Tamanoi F, Yokoyama K, Ghomashchi F, Esson K, Gould MB: The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Lett (1995) 91:169-175.
67. Stayrook KR, McKinzie JH, Barbhaiya LH, Crowell PL: Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells. Anticancer Res (1998) 18:823-828.
68. Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna GW: The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res (1996) 56:1727-1730.
69. Hahn SM, Kiel K, Morrison BW, Mohiuddin MM, Thomas D, Smith D, Brown R, Pramanik B, Kher U, Deutsch P, McKenna WG Phase I trial of the farnesyl protein transferase (PFTase) inhibitor L-778123 in combination with radiotherapy. Proc Am Assoc Clin Oncol (2000) 19:906.
70. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su D-S, Danishefsky SJ, Rosen N: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA (1998) 95:1369-1374.
71. Hurwitz HI, Amado R, Prager D, Hecht JR, Cohen DP, Conway D, Kadib L, Mayers A, Calzetta A, Statkevich P, Cutler DL, Rosen LS Phase I pharmacokinetic trial of the farnesyl transferase inhibitor Sch-66336 plus Gemcitabine in advanced cancers. Proc Am Assoc Clin Oncol (2000) 19:717.
72. Patnaik A A phase I study of R115777 with Gemcitabine in patients with advanced solid malignancies. Proc Am Assoc Clin Oncol (2000) 19:5A.
73. Sharma S, Britten C, Spriggs D, Rosen N, Soignet S, Pezzulli S, Patnaik A, Kher U, Arena C, Deutsch P, Yao S, Rowinsky E A phase I and PK study of farnesyl transferase inhibitor L-778123 administered as a seven day continuous infusion in combination with Paclitaxel. Proc Am Assoc Ciln Oncol (2000) 19:719.
74. Khuri FR, Glisson BS, Meyers ML, Herbst RS, Thall PF, Munden RF, Bangert S, Cascino M, Blumenschein G, Pister K, Hong WK Phase I study of farnesyl transferase inhibitor Sch-66336 with Paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy/safety. Proc Am Assoc Clin Oncol (2000) 19:799.
75. Gibbs JB: Mechanism-based target identification and drug discovery in cancer research. Science (2000) 287:1969-1972.
76. RHÔNE POULENC RORER SA (Baudoin B, Dereu N, El-Ahmad Y, Jiminet P, Le Brun A): Di-substituted naphthyl derivatives, preparation thereof, pharmaceutical compositions containing them. WO-09941242 (1999).
77. RHÔNE POULENC RORER SA (Hardy JC, Dereu N, Le Brun A, Baudoin B, Clerc F, Jimonet P, El-Ahmad Y): Condensed heterocyclic system derivatives, preparation, pharmaceutical compositions containing them. WO-09941248 (1999).
78. RHÔNE POULENC RORER SA (Hardy JC, Dereu N, Le Brun A, Clerc F, Jimonet P, Baudoin B, El-Ahmad Y): New 4-amino chroman or thiochroman 8-carboxamide derivative farnesyl transferase inhibitors, used as antiproliferative agents, e.g. for treating cancer. FR-02774987 (1999).
79. RHONE POULENC RORER SA (Dereu N, Le Brun A, Jimonet P, Baudoin B, El-Ahmad Y): New naphthyl carbonyl or sulfonyl oxopiperazine farnesyl transferase inhibitors, used as antiproliferative agents, e.g. for treating cancer. FR-02774985 (1999).
80. SCRAS (Kim Sun H): Prenyl transferase inhibitors. WO-0996522 (1999).
81. SCRAS (Prevost G, Lonchampt, MO): Utilisation d'inhibiteurs de prenyltransferase pour préparer un médicament destiné à traiter les pathologies qui resultent de la fixation membranaire de la proteine G hétérotrimérique. FR-02780892 (2000).
82. LG CHEMICAL LTD (Chung HH, Kim JH, Koh JS, Kwak TH, Lee HI, Park KW, Ro SG, Jung WH, Kim SW, Lee JH, Moon KD, Shin YS): Hydantoin derivatives having an inhibitory activity for farnesyl transferase. WO-09905117 (1999).
83. LG CHEMICAL LTD (Ahn IA, Chung HH, Kim HS, Kim JH, Kim KH, Koh JS, Kwak TH, Lee HI, Lee SH, Oh YH, Ro SG, Choi TS, Kim CM, Lee JH, Shin YS): Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof. WO-09938862 (1999).
84. LG CHEMICAL LTD (Ahn IA, Chung HH, Jeong SW, Kim HS, Kim JH, Kim KH, Koh JS, Kwak TH, Lee HI, Lee SH, Ro SG, Yoo JK, Choi TS, Jung WH, Lee JH, Shin YS): Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof. WO-09928315 (1999).
85. YUHAN CORP (Hwang SH, Kim JG, Lee BY, Bhang KH, Hwang HJ, Jung YH, Park YH, Shim JH, Sim WJ, Yi WH): Thiourea derivatives or non-toxic salts thereof for inhibiting ras-transformed cell growth. WO-09912912 (1999).
86. ZENECA (Wardleworth JM, Drake DJ): Farnesyl transferase inhibitors. WO-09941235 (1999).
87. ZENECA (Arnould JC): Imidazole derivatives and their use as farnesyl protein transferase inhibitors. WO-09920612 (1999).
88. ZENECA (Arnould JC): Imidazole derivatives and their use as farnesyl protein transferase inhibitors. WO-09920611 (1999).
89. PIERRE FABRE MEDICAMENT (Gotteland JP, Halazy S, Perrin D, Hill B): Novel sulphonamides derived from substituted anilines useful as medicines. WO-09906376 (1999).
90. PFIZER INC (Lyssikatos JP, La Greca SB): Alkynyl-substituted quinilin-2-one derivatives useful as anticancer agents. WO-00012499 (2000).
91. PFIZER INC (Lyssikatos JP, Yang BV, La Greca SB): Quinolin-2-one derivatives useful as anticancer agents. WO-00012498 (2000).
92. PARACURE INC (Adekenov SM): Pharmaceutical compositions of arglabin and arglabin derivatives. WO-09848789 (1998).
93. JANSSEN PHARMA (Cools MLL, Van Wauwe JPF, End DW): Farnesyl protein transferase inhibitors for treating arthropathies. WO-00001386 (2000).
94. JOHNS HOPKINS UNIVERSITY (Campochiaro PA): Method for treatment of ocular neovascularization. WO-09857654 (1998).
95. UNIVERSITY OF PENNSYLVANIA & UNIVERSITY OF PITTSBURGH (Hamilton AD, Bernhard EJ, Muschel RJ, Sebti SM, McKenna WG): Sensrtization of cells to radiation and chemotherapy. WO-09738697 (1997).
96. JANSSEN PHARMA (Floren WJ, Van Ginckel RF, Wouters WBL, End DW): Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties. WO-00001411 (2000).
97. WARNER LAMBERT CO (Leopold J, Newton RS): Combinations of protein farnesyltransferase and HMGCoA reductase inhibitors and their use to treat cancer. WO-09958505 (1999).
98. MERCK & CO INC (Heimbrook DC, Stirdivant SM, Oliff AI, Graham SL, Koblan KS): A method of treating cancer. WO-00016778 (2000).
99. MERCK & CO INC (Heimbrook DC, Stirdivant SM, Oliff AI, Graham SL, Koblan KS): A method of treating cancer. WO-00016626 (2000).
100. MERCK & CO INC (Oliff AI, Gibbs JB, Graham SL, Kohl N, Moasser MM, Rosen N, Prendergast GC, Sepp-Lorenzino L): A method of treating cancer. WO-09854966 (1998).
101. SCHERING CORP (Girijavallabhan V, Nielsen LL, Doll RJ, Ganguly A, Bishop WR, Catino JJ, Cutler DL, Liu M, Kirschmeier P): Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases. WO-09932114 (1999).
102. MERCK & CO (Burns HD, Eng WS, Gibson RE): Radiolabeled farnesyl-protein transferase inhibitors. WO-09900654 (1999).
103. SCHERING CORP (Strickland C, Weber PC): Crystalline farnesyl protein transferase compositions and methods for use. WO-00012543 (2000).